In February, 1994 Baxter Healthcare Corporation withdrew from world markets Gammagard®, an immunoglobulin administered intravenously to those with acquired or congential immune disorders, after 112 people in the U.S. were reported having symptoms of hepatitis C, the most fatal form of the this liver disease. Also withdrawn at the same time was a companion drug, […]
Product Liability / Defective Products
Ending Secrecy In Defective Product Litigation: New Federal Reporting Rule For Consumer Products
Manufacturers of consumer products, as of January 1, 1991, are required to report to the Consumer Product Safety Commission settlements in cases involving “grievous bodily injury or death” caused by defective products. The new legislation, 15 U.S. C. 2084, is an important advancement for consumers, since former regulations were vague and easily avoided. Previous rules […]
Carcinogens Everywhere: Lead In Children: Old Story – New Data
BY Peter Montague RACHEL’S ENVIRONMENT & HEALTH WEEKLY U.S. EPA [Environmental Protection Agency] published a report in 1998 saying that 100% of the outdoor air in the continental U.S. is contaminated with eight cancer-causing industrial chemicals at levels that exceed EPA’s “benchmark” safety standards.[1] Alaska and Hawaii were excluded from the analysis for lack of […]
Breast Implants: Fact V. Fiction In The Harvard And Mayo Clinic Studies
The “Harvard Nurses Study,” officially titled Silicone Breast Implants and Connective Tissue Disease, was conducted by researchers at Harvard Medical School, the Harvard School of Public Health, and Brigham and Women’s Hospital in Boston. The study, first presented at the October 1994 meeting of the American College of Rheumatology and published June 22, 1995 in […]
Breast Implants: Dow’s Manipulation Of Public Opinion And The Media
The following document was obtained in discovery in breast implant litigation. It contains a detailed proposal by Burson-Marsteller Public Relations of October 14, 1991 outlining Dow’s public relations efforts prior to anticipated FDA hearings on the safety of breast implants. BURSON-MARSTELLER PUBLIC RELATIONS October 14, 1991 PRE-FDA HEARING MEDIA PLAN Objectives Secure maximum exposure for […]
